Difference between revisions of "Envafolimab (Enweida)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 15: Line 15:
  
 
==History of changes in NMPA indication==
 
==History of changes in NMPA indication==
*2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors who have experienced disease progression following prior treatment and have no satisfactory alternative treatment options.
+
*2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced [[:Category:Malignant solid neoplasm|solid tumors]] who have experienced disease progression following prior treatment and have no satisfactory alternative treatment options.
*2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced colorectal cancer who have experienced disease progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
+
*2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced [[colorectal cancer]] who have experienced disease progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
  
 
==Also known as==
 
==Also known as==
Line 26: Line 26:
 
[[Category:Anti-PD-L1 antibodies]]
 
[[Category:Anti-PD-L1 antibodies]]
  
 +
[[Category:Colorectal cancer medications]]
 
[[Category:MSI-H or dMMR medications]]
 
[[Category:MSI-H or dMMR medications]]
  
 
[[Category:NMPA approved drugs]]
 
[[Category:NMPA approved drugs]]

Revision as of 14:11, 5 June 2023

Note: Envafolimab is approved in China, but does not appear to have a brand name at this time.

General information

Class/mechanism: PD-L1 antibody.
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Toxicity management

Diseases for which it is used

History of changes in NMPA indication

  • 2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors who have experienced disease progression following prior treatment and have no satisfactory alternative treatment options.
  • 2021-11-26: Approved for adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced colorectal cancer who have experienced disease progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

Also known as

  • Code name: KN 035